Appendix 3Y Change of Director's Interest Notice
CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to...
Read More
Appendix 3Y Change of Director's Interest Notice
Information or documents not available now must be given to ASX as...
Read More
SCIENTIFIC COMMUNIQUÉ IX
Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...
Read More
Operations Update Webinar
https://vimeo.com/516430955/8f3e88ca5chttps://vimeo.com/516430955/8f3e88ca5c
Read More
CLINUVEL Reports Tenth Consecutive Half Year Net Profit
KEY HIGHLIGHTS, HALF YEAR ENDED 31 DECEMBER 2020 Consolidated Entity Result Change...
Read More
Appendix 4D Half Year Report
Results For Announcement To The Market ($A’000) Revenues from continuing activities Increased...
Read More
Financial Results Half Year Ended 31 December 2020
Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...
Read More
SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More
Kommuniqué I
Liebe Freunde, Aktionäre, Wir sind in ein neues Jahr eingetreten, eines voller...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 28 January 2021 CLINUVEL PHARMACEUTICALS LTD today announced its Appendix...
Read More
CLINUVEL Communiqué I
Dear friends, shareholders, We have entered a new year, one brimmed with...
Read More
H.C. Wainwright Bioconnect Conference 2021
12 January 2021 https://vimeo.com/clinuvel/review/499638631/b90c97ddb9 Download Presentation & Speaker Notes
Read More